24 research outputs found

    Tonometria Gastrointestinal no Perioperatório do Transplante Hepático: Uma Revisão Integrativa

    Get PDF
    Introdução: A tonometria gástrica é uma ferramenta útil para examinar a perfusão esplâncnica regional por permitir o fornecimento de uma avaliação indireta do estado do enxerto hepático. Isso ocorre devido à hipoperfusão esplâncnica ser um parâmetro crítico no contexto do transplante de fígado, estando associada ao desenvolvimento de problemas como insuficiência hepática aguda e falência de múltiplos órgãos. Objetivo: Analisar os efeitos da tonometria gastrointestinal no perioperatório dos pacientes submetidos ao transplante hepático. Metodologia: Trata-se de uma Revisão Integrativa realizada nas bases de dados PubMed e BVS. Foram utilizados os descritores: “Tonometry”, “Splanchnic circulation” e “Liver transplantation”, incluindo o operador booleano “AND”, e selecionados artigos de relevância para o tema. Foram selecionados inicialmente 24 artigos, todos publicados nos últimos 20 anos, em português e/ou inglês. Após análise, seis artigos corresponderam ao objetivo proposto. Resultado: Observou-se que a diferença entre a PraCO2 no final da cirurgia e na fase anepática foi maior em pacientes sem disfunção do enxerto hepático. Foi identificada uma correlação positiva entre ΔpraCO2 e o pico de ALT após o transplante de fígado. Em outro estudo, verificou-se que a presença de enzimas hepáticas elevadas e a piora da função hepática sintética, coagulopatia e encefalopatia estava relacionada à má função do enxerto. Também foi comprovado que o pH gástrico intramucoso pode predizer a funcionalidade precoce do enxerto. Em um grupo com disfunção hepática, os pacientes apresentaram pH gástrico intramucoso abaixo de 7,3 no período perioperatório, mantendo-se baixo até a 24ª hora pós-operatória, enquanto o grupo sem disfunção apresentou pH gástrico intramucoso acima de 7,3, exceto na fase anepática, quando ficou abaixo desse valor. Conclusão: Descreve-se a utilidade da tonometria gastrointestinal para monitorar a circulação esplâncnica e a função do enxerto hepático durante o transplante hepático. Embora alguns estudos ofereçam suporte a essa afirmação, esta revisão apresenta limitações devido à quantidade restrita de artigos disponíveis, o que a impede de abranger uma ampla gama de evidências científicas

    Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

    Get PDF
    Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

    Resumos em andamento - Saúde Coletiva

    No full text
    Resumos em andamento - Saúde Coletiv

    Resumos em andamento - Saúde Coletiva

    No full text
    Resumos em andamento - Saúde Coletiv

    Núcleos de Ensino da Unesp: artigos 2009

    No full text

    Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

    No full text
    Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.13Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

    Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

    No full text

    Alirocumab and cardiovascular outcomes after acute coronary syndrome

    No full text
    BACKGROUN

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text
    corecore